z-logo
open-access-imgOpen Access
Treatment of malignant pheochromocytoma with combination chemotherapy.
Author(s) -
Harry R. Keiser,
D. S. Goldstein,
James L. Wade,
Frank L. Douglas,
Steven D. Averbuch
Publication year - 1985
Publication title -
hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.986
H-Index - 265
eISSN - 1524-4563
pISSN - 0194-911X
DOI - 10.1161/01.hyp.7.3_pt_2.i18
Subject(s) - medicine , vincristine , chemotherapy , pheochromocytoma , dacarbazine , cyclophosphamide , combination chemotherapy , regimen , blood pressure , chemotherapy regimen , radiation therapy , surgery , oncology
Three patients with rapidly progressive, disseminated malignant pheochromocytoma were treated with a combination chemotherapeutic regimen consisting of cyclophosphamide, vincristine, and dacarbazine in repeated 21- to 28-day cycles. All three patients had a marked decrease in blood pressure and an improvement in performance status within the first few cycles of treatment. At a follow-up of 6 to 13 months all patients continue to receive chemotherapy with further regression of tumor in two and stable disease in one. Their blood pressure is normal with minimal or no antiadrenergic therapy. Therapy has been well tolerated; moderate reversible granulocytopenia, neurotoxicity, and one episode of pneumonitis have been the major toxicities encountered. Thus, combination chemotherapy appears to be effective for symptomatic malignant pheochromocytoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom